Movement Disorders Feature Archive

Multiple System Atrophy: A Common Form of Atypical Parkinsonism

Multiple System Atrophy: A Common Form of Atypical Parkinsonism

Multiple system atrophy is a rare, progressive neurodegenerative condition for which there is currently no cure.

Parkinson Disease Prevalence Severely Underestimated: Parkinson's Foundation Prevalence Project

Parkinson Disease Prevalence Severely Underestimated: Parkinson's Foundation Prevalence Project

The Parkinson's Foundation Prevalence Project estimates that within the next 2 years, 930,000 people in the United States will be living with the condition; that number is anticipated to rise to 1.2 million by 2030.

The Future of Freezing of Gait in Parkinson's: Exploring Potential Treatments and Preventive Strategies

The Future of Freezing of Gait in Parkinson's: Exploring Potential Treatments and Preventive Strategies

More than half of patients diagnosed with Parkinson disease experience freezing of gait.

Emerging Innovations in Parkinson Disease Treatment: Q&A With Dr Matthew Brodsky

Emerging Innovations in Parkinson Disease Treatment: Q&A With Dr Matthew Brodsky

Surgical interventions for Parkinson disease are experiencing a swell in innovation, thanks in part to the entry of two additional medical device companies into a field previously dominated by one company.

Understanding Impulse Control Disorders in Parkinson Disease: Developments and Treatments

Understanding Impulse Control Disorders in Parkinson Disease: Developments and Treatments

In this article, we explore research findings to provide a deeper understanding of the factors associated with increased risk for impulse control disorders in Parkinson disease. Deputy Director of the Parkinson's UK charity, Professor David Dexter, also provides insights on the mechanisms of impulse control disorders and the implications of new findings on the management of Parkinson disease.

Neurosurgery in Parkinson Disease: A Brief History and Look Forward

Neurosurgery in Parkinson Disease: A Brief History and Look Forward

Although deep brain stimulation, similar to all Parkinson disease therapies, cannot cure, modify, or slow progression of the disease, some recent research suggests that the symptom alleviation and quality-of-life improvement it provides might lead to mild improvements in longevity.

Old Challenges and New Directions in Managing Tardive Dyskinesia

Old Challenges and New Directions in Managing Tardive Dyskinesia

"Since the current generation of psychiatrists has been raised on second-generation antipsychotics and has relatively little experience with first-generation antipsychotics, keeping tardive dyskinesia in mind is not, on the whole, part of their experience or training," said Christoph U. Correll, MD.

Palliative Care in Movement Disorders: Recommendations for Improvement

Palliative Care in Movement Disorders: Recommendations for Improvement

Parkinsonism syndromes are associated with progressive disability and increased mortality, with symptom burden comparable to that of advanced cancer.

Anesthesia in Parkinson Disease Requires Cautious Care

Anesthesia in Parkinson Disease Requires Cautious Care

Anesthetic medications have been identified as a potential cause of morbidity in this population due to their interaction with the drugs used to manage Parkinson disease.

Sex Differences in Parkinson Disease: Implications for Diagnosis, Treatment

Sex Differences in Parkinson Disease: Implications for Diagnosis, Treatment

Several studies have uncovered sex-dependent variations in the symptomatic manifestations of Parkinson disease, as well as in the response to dopamine therapies.

Predicting Rates and Patterns of Progression in Parkinson Disease

Predicting Rates and Patterns of Progression in Parkinson Disease

Numerous factors are likely contribute to the rate of progression, with different combinations of factors showing relevance for individual patients.

Cognitive Impairment in Multi-System Atrophy: Is It Time to Update Diagnostic Criteria?

Cognitive Impairment in Multi-System Atrophy: Is It Time to Update Diagnostic Criteria?

Although evidence of cognitive impairment in MSA is admittedly more limited than in Parkinson disease, it is now substantial enough to address modification of diagnostic criteria to include the potential for cognitive impairment at any stage of the disease.

Atypical Parkinsonian Disorders: Reviewing the Complex Web of Proteinopathies

Atypical Parkinsonian Disorders: Reviewing the Complex Web of Proteinopathies

While parkinsonian disorders share a common mechanism of protein aggregation, manifestations are quite varied.

Defining Unique Needs for Palliative and Hospice Care in Huntington Disease

Defining Unique Needs for Palliative and Hospice Care in Huntington Disease

Research has shown significant gaps in knowledge on palliative services among neurology residents, resulting in low referral rates.

Managing Dystonia With Noninvasive Brain Stimulation: Therapy Update

Managing Dystonia With Noninvasive Brain Stimulation: Therapy Update

There is speculation that dystonia is the result of dysfunction occurring in either the cerebellum or basal ganglia or as a result of an abnormal interaction between the two.

MRI in Parkinson Disease: Expanding Usability for Better Diagnostics

MRI in Parkinson Disease: Expanding Usability for Better Diagnostics

MRI may be used to identify Parkinson disease biomarkers that can inform diagnosis, track disease progression, and elucidate the neurobiological underpinnings of symptoms.

Tardive Dyskinesia: Experts Weigh in on New Treatments, Ongoing Challenges

Tardive Dyskinesia: Experts Weigh in on New Treatments, Ongoing Challenges

The main challenge is to determine when treating tardive dyskinesia with any pharmacological agent would provide a net benefit.

Ocular Tremor in Parkinson's Disease: Inherent or Compensatory?

Ocular Tremor in Parkinson's Disease: Inherent or Compensatory?

Debate continues as to whether ocular tremor represents a clinical marker of Parkinson's disease or a compensatory movement related to other bodily tremors.

Identifying Prodromal Symptoms of Ataxia Type 2 for Early Intervention

Identifying Prodromal Symptoms of Ataxia Type 2 for Early Intervention

Investigators identified a series of prodromal signs that appear anywhere from 1 to 18 years before a clinical diagnosis of SCA2.

New Clinical Guidelines: Distinguishing Variations of Progressive Supranuclear Palsy

New Clinical Guidelines: Distinguishing Variations of Progressive Supranuclear Palsy

New guidelines for progressive supranuclear palsy provide very specific and sensitive criteria that allow for identification of clinical features of the disease at much earlier stages.

Impulse Control Disorders in Parkinson's Disease: Building Physician, Patient Awareness

Impulse Control Disorders in Parkinson's Disease: Building Physician, Patient Awareness

A patient should be notified of the possibility of developing an ICD before initiating any dopaminergic treatment for PD, particularly dopamine agonists.

Effect of Depression and Anxiety on Cognition in Parkinson's Disease

Effect of Depression and Anxiety on Cognition in Parkinson's Disease

Comorbid psychological conditions affect cognitive function in Parkinson's disease, and treatment can be complicated by overlapping symptoms.

The Troubling Link Between Parkinson's and Smoking: Can We Deny the Benefits?

The Troubling Link Between Parkinson's and Smoking: Can We Deny the Benefits?

Research has shown a confounding link between nicotine and reduced risk of Parkinson's disease.

Treatment Challenges in Parkinson's Disease Psychosis

Treatment Challenges in Parkinson's Disease Psychosis

Parkinson's disease psychosis is underreported and is difficult to treat, but a new drug in late-stage development is a promising therapy.

Advancements in Deep Brain Stimulation for Parkinson's

Advancements in Deep Brain Stimulation for Parkinson's

The ongoing INTREPID clinical trial is evaluating the safety and effectiveness of the Vercise™ DBS System.

Exploring the Role of GCH1 in Parkinson's Disease

Exploring the Role of GCH1 in Parkinson's Disease

The role of GCH1 mutations in Parkinson's disease is complicated by the mutation's seemingly exclusive role in dopa-responsive dystonia.

Advancing Applications of Closed-Loop Neurostimulation

Advancing Applications of Closed-Loop Neurostimulation

Closed-loop neurostimulation technology is being investigated for movement disorders, headache, and even some neuropsychiatric disorders.

Motion-Sensing Technology to Monitor Parkinson's Disease

Motion-Sensing Technology to Monitor Parkinson's Disease

Motion-sensing technology provides a lot of data, but researchers still aren't sure if it's clinically useful.

The Search for Neuroprotective Parkinson's Therapies

The Search for Neuroprotective Parkinson's Therapies

Several anti-diabetes agents hold promise for Parkinson's disease-related neurodegeneration.

Sign Up for Free e-newsletters



CME Focus